Key Points
- Director Christopher Michael Lyons bought 7,534 shares on March 2 at an average of $2.90 for $21,848.60, raising his stake to 8,292 shares (a reported 993.93% increase), and he also acquired 758 shares on Feb 25 at $2.96.
- SINT opened at $2.87 (up 4.4%), trades in a 12‑month range of $1.71–$6.78, and the company has a market capitalization of about $10.56 million with a negative P/E of -0.51.
- About 18.38% of the stock is held by institutions and analyst coverage is mixed—one Buy and one Sell for an average "Hold" rating and an average price target of $16 (Weiss reiterated a sell while Ascendiant cut its target to $16 but kept a buy).
Sintx Technologies, Inc. (NASDAQ:SINT - Get Free Report) Director Christopher Michael Lyons acquired 7,534 shares of Sintx Technologies stock in a transaction on Monday, March 2nd. The shares were purchased at an average cost of $2.90 per share, for a total transaction of $21,848.60. Following the acquisition, the director owned 8,292 shares in the company, valued at approximately $24,046.80. This represents a 993.93% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Christopher Michael Lyons also recently made the following trade(s):
- On Wednesday, February 25th, Christopher Michael Lyons acquired 758 shares of Sintx Technologies stock. The stock was acquired at an average price of $2.96 per share, for a total transaction of $2,243.68.
Sintx Technologies Trading Up 4.4%
NASDAQ SINT opened at $2.87 on Wednesday. Sintx Technologies, Inc. has a 12 month low of $1.71 and a 12 month high of $6.78. The stock has a 50-day simple moving average of $3.26 and a 200 day simple moving average of $3.67. The company has a market capitalization of $10.56 million, a PE ratio of -0.51 and a beta of 0.67.
Institutional Investors Weigh In On Sintx Technologies
Large investors have recently modified their holdings of the business. Virtus Wealth Solutions LLC acquired a new stake in shares of Sintx Technologies during the third quarter worth about $388,000. Veracity Capital LLC lifted its holdings in shares of Sintx Technologies by 10.3% during the 3rd quarter. Veracity Capital LLC now owns 79,928 shares of the company's stock valued at $327,000 after purchasing an additional 7,464 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Sintx Technologies by 53.4% in the 4th quarter. Geode Capital Management LLC now owns 26,624 shares of the company's stock valued at $103,000 after purchasing an additional 9,265 shares during the period. 18.38% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several research firms recently weighed in on SINT. Weiss Ratings reissued a "sell (e+)" rating on shares of Sintx Technologies in a research note on Thursday, January 22nd. Ascendiant Capital Markets lowered their target price on shares of Sintx Technologies from $25.00 to $16.00 and set a "buy" rating for the company in a research note on Monday, December 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Sintx Technologies currently has an average rating of "Hold" and an average price target of $16.00.
Get Our Latest Report on Sintx Technologies
Sintx Technologies Company Profile
(
Get Free Report)
Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx's primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.
The company's core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
